A new study links telomere length genetics to IPF risk, showing how rare variants and polygenic scores may guide future screening and precision care.

What is Idiopathic Pulmonary Fibrosis (IPF)? IPF is a chronic, progressive, lung disease characterized by disabling shortness of breath, declining exercise capacity and extensive formation of scar ...

Deupirfenidone, a potential new treatment for idiopathic pulmonary fibrosis, is set to be tested in a phase 3 trial this year after a successful phase 2b trial and meeting with the FDA, according to a ...

If you have scarring in your lungs, you may have been diagnosed with pulmonary fibrosis. When the reason for this scarring is unknown, your condition is called idiopathic pulmonary fibrosis (IPF). You ...

Early diagnosis and treatment in IPF and PPF are vital, as fibrosis is irreversible and current therapies only slow progression. Current IPF treatments, pirfenidone and nintedanib, have significant ...

What Is Jascayd, and Why Does It Matter? Jascayd (nerandomilast) is a new oral medicine approved to treat idiopathic pulmonary fibrosis (IPF) in adults. IPF is a rare and serious condition that causes ...

The FDA granted orphan drug designation to deupirfenidone, also known as LYT-100, for treating patients with idiopathic pulmonary fibrosis, according to a press release from PureTech Health.The ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Swigris: Before we ...